Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 346

1.

Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.

Montoro J, Ceberio I, Hilden P, Maloy MA, Barker J, Castro-Malaspina H, Dahi P, Koehne G, Perales MA, Ponce D, Sauter C, Shaffer B, Tamari R, Young JW, Giralt SA, O'Reilly RJ, Jakubowski AA, Papadopoulos EB.

Biol Blood Marrow Transplant. 2019 Oct 13. pii: S1083-8791(19)30659-7. doi: 10.1016/j.bbmt.2019.10.003. [Epub ahead of print]

PMID:
31618690
2.

Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma.

Bryant AR, Hilden P, Giralt S, Chung DJ, Maloy M, Landau H, Landgren O, Scordo M, Shah G, Smith EL, O'Reilly RJ, Perales MA, Koehne G.

Biol Blood Marrow Transplant. 2019 Sep 5. pii: S1083-8791(19)30563-4. doi: 10.1016/j.bbmt.2019.08.023. [Epub ahead of print]

PMID:
31493537
3.

Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction.

O'Reilly RJ, Prockop S, Hasan A, Doubrovina E.

Bone Marrow Transplant. 2019 Aug;54(Suppl 2):759-764. doi: 10.1038/s41409-019-0614-1. Review.

PMID:
31431697
4.

Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Bhatt V, Hilden P, Smith M, Thoren K, Cho C, Shah GL, Maloy MA, Papadopoulos EB, Jakubowski AA, Avecilla ST, O'Reilly RJ, Castro-Malaspina H, Tamari R, Shaffer BC, Boelens JJ, Perales MA, Giralt SA.

Biol Blood Marrow Transplant. 2019 Aug;25(8):1526-1535. doi: 10.1016/j.bbmt.2019.02.021. Epub 2019 Mar 1.

PMID:
30831208
5.

Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Hsu M, Jakubowski AA, Shah GL, Cho C, Maloy MA, Avecilla ST, Papadopoulos EB, Gyurkocza B, Castro-Malaspina H, Tamari R, O'Reilly RJ, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1136-1141. doi: 10.1016/j.bbmt.2018.12.842. Epub 2019 Jan 6.

PMID:
30625387
6.

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study.

Modak S, Le Luduec JB, Cheung IY, Goldman DA, Ostrovnaya I, Doubrovina E, Basu E, Kushner BH, Kramer K, Roberts SS, O'Reilly RJ, Cheung NV, Hsu KC.

Oncoimmunology. 2018 May 10;7(8):e1461305. doi: 10.1080/2162402X.2018.1461305. eCollection 2018.

7.

SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

Haddad E, Logan BR, Griffith LM, Buckley RH, Parrott RE, Prockop SE, Small TN, Chaisson J, Dvorak CC, Murnane M, Kapoor N, Abdel-Azim H, Hanson IC, Martinez C, Bleesing JJH, Chandra S, Smith AR, Cavanaugh ME, Jyonouchi S, Sullivan KE, Burroughs L, Skoda-Smith S, Haight AE, Tumlin AG, Quigg TC, Taylor C, Dávila Saldaña BJ, Keller MD, Seroogy CM, Desantes KB, Petrovic A, Leiding JW, Shyr DC, Decaluwe H, Teira P, Gillio AP, Knutsen AP, Moore TB, Kletzel M, Craddock JA, Aquino V, Davis JH, Yu LC, Cuvelier GDE, Bednarski JJ, Goldman FD, Kang EM, Shereck E, Porteus MH, Connelly JA, Fleisher TA, Malech HL, Shearer WT, Szabolcs P, Thakar MS, Vander Lugt MT, Heimall J, Yin Z, Pulsipher MA, Pai SY, Kohn DB, Puck JM, Cowan MJ, O'Reilly RJ, Notarangelo LD.

Blood. 2018 Oct 25;132(17):1737-1749. doi: 10.1182/blood-2018-03-840702. Epub 2018 Aug 28.

PMID:
30154114
8.

Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.

Rondon-Clavo C, Scordo M, Hilden P, Shah GL, Cho C, Maloy MA, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Gyurkocza B, Castro-Malaspina H, Tamari R, Shaffer BC, Perales MA, Jaimes EA, Giralt SA.

Biol Blood Marrow Transplant. 2018 Dec;24(12):2517-2522. doi: 10.1016/j.bbmt.2018.07.031. Epub 2018 Jul 26.

PMID:
30055353
9.

B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation.

Miggelbrink AM, Logan BR, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Abdel-Azim H, Prockop SE, Shyr D, Decaluwe H, Hanson IC, Gillio A, Dávila Saldaña BJ, Eibel H, Hopkins G, Walter JE, Whangbo JS, Kohn DB, Puck JM, Cowan MJ, Griffith LM, Haddad E, O'Reilly RJ, Notarangelo LD, Pai SY.

Blood. 2018 Jun 28;131(26):2967-2977. doi: 10.1182/blood-2017-10-809822. Epub 2018 May 4.

10.

TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.

Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AN, Selvakumar A, O'Reilly RJ, Liu C, Cheung NV.

JCI Insight. 2018 Feb 22;3(4). pii: 97805. doi: 10.1172/jci.insight.97805. eCollection 2018 Feb 22.

11.

Allogeneic Matched Related Donor Bone Marrow Transplantation for Pediatric Patients With Severe Aplastic Anemia Using "Low-dose" Cyclophosphamide, ATG Plus Fludarabine.

Takpradit C, Prockop SE, Kernan NA, Scaradavou A, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F.

J Pediatr Hematol Oncol. 2018 May;40(4):e220-e224. doi: 10.1097/MPH.0000000000001106.

12.

Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.

Tamari R, Oran B, Hilden P, Maloy M, Kongtim P, Papadopoulos EB, Rondon G, Jakubowski AA, Andersson BS, Devlin SM, Ahmed S, Popat UR, Ponce D, Chen J, Sauter C, Young JW, de Lima M, Perales MA, O'Reilly RJ, Giralt SA, Champlin RE, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2018 May;24(5):1079-1087. doi: 10.1016/j.bbmt.2018.01.001. Epub 2018 Jan 8.

13.

Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Cho C, Hsu M, Barba P, Maloy MA, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, Jakubowski AA, Koehne G, Meagher RC, O'Reilly RJ, Papadopoulos EB, Ponce DM, Tamari R, van den Brink MRM, Young JW, Devlin SM, Perales MA.

Bone Marrow Transplant. 2017 Dec;52(12):1629-1636. doi: 10.1038/bmt.2017.197. Epub 2017 Oct 9.

14.

Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Shah GL, Scordo M, Kosuri S, Herrera DA, Cho C, Devlin SM, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Jakubowski AA, Papadopoulos EB, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Perales MA, Giralt SA, Tamari R.

Biol Blood Marrow Transplant. 2018 Jan;24(1):142-149. doi: 10.1016/j.bbmt.2017.08.040. Epub 2017 Sep 22.

15.

Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.

Scordo M, Shah GL, Kosuri S, Herrera DA, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Avecilla ST, Meagher RC, Carlow DC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Tamari R, Perales MA, Giralt SA, Shaffer BC.

Biol Blood Marrow Transplant. 2018 Jan;24(1):133-141. doi: 10.1016/j.bbmt.2017.08.033. Epub 2017 Sep 1.

16.

T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.

Jakubowski AA, Petrlik E, Maloy M, Hilden P, Papadopoulos E, Young JW, Boulad F, Castro-Malaspina H, Tamari R, Dahi PB, Goldberg J, Koehne G, Perales MA, Sauter CS, O'Reilly RJ, Giralt S.

Biol Blood Marrow Transplant. 2017 Oct;23(10):1685-1694. doi: 10.1016/j.bbmt.2017.06.024. Epub 2017 Jul 19.

17.

The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.

Kosuri S, Adrianzen Herrera D, Scordo M, Shah GL, Cho C, Devlin SM, Maloy MA, Nieves J, Borrill T, Carlow DC, Avecilla ST, Meagher RC, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Koehne G, Gyurkocza B, Castro-Malaspina H, Shaffer BC, Tamari R, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):2004-2011. doi: 10.1016/j.bbmt.2017.07.012. Epub 2017 Jul 18.

18.

A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.

Spitzer B, Jakubowski AA, Papadopoulos EB, Fuller K, Hilden PD, Young JW, Barker JN, Koehne G, Perales MA, Hsu KC, van den Brink MR, Kernan NA, Prockop SE, Scaradavou A, Castro-Malaspina H, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2017 Dec;23(12):2088-2095. doi: 10.1016/j.bbmt.2017.07.004. Epub 2017 Jul 12.

19.

Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.

Getta BM, Roshal M, Zheng J, Park JH, Stein EM, Levine R, Papadopoulos EB, Jakubowski AA, Kernan NA, Steinherz P, O'Reilly RJ, Perales MA, Giralt SA, Tallman MS, Shaffer BC.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1879-1886. doi: 10.1016/j.bbmt.2017.06.026. Epub 2017 Jul 8.

20.

Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.

Tuckett AZ, Thornton RH, O'Reilly RJ, van den Brink MRM, Zakrzewski JL.

J Hematol Oncol. 2017 May 16;10(1):109. doi: 10.1186/s13045-017-0478-z.

21.

Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study.

Mehta PA, Davies SM, Leemhuis T, Myers K, Kernan NA, Prockop SE, Scaradavou A, O'Reilly RJ, Williams DA, Lehmann L, Guinan E, Margolis D, Baker KS, Lane A, Boulad F.

Blood. 2017 Apr 20;129(16):2308-2315. doi: 10.1182/blood-2016-09-743112. Epub 2017 Feb 8.

22.

Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

Goldberg JD, Zheng J, Ratan R, Small TN, Lai KC, Boulad F, Castro-Malaspina H, Giralt SA, Jakubowski AA, Kernan NA, O'Reilly RJ, Papadopoulos EB, Young JW, van den Brink MR, Heller G, Perales MA.

Leuk Lymphoma. 2017 Aug;58(8):1859-1871. doi: 10.1080/10428194.2016.1265113. Epub 2017 Jan 10.

23.

Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Barba P, Hilden P, Devlin SM, Maloy M, Dierov D, Nieves J, Garrett MD, Sogani J, Cho C, Barker JN, Kernan NA, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Prockop S, Sauter C, Tamari R, van den Brink MR, Avecilla ST, Meagher R, O'Reilly RJ, Goldberg JD, Young JW, Giralt S, Perales MA, Ponce DM.

Biol Blood Marrow Transplant. 2017 Mar;23(3):452-458. doi: 10.1016/j.bbmt.2016.12.633. Epub 2016 Dec 23.

24.

Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.

Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, Maloy MA, Barker JN, Castro-Malaspina H, Jakubowski AA, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Tamari R, van den Brink MRM, Young JW, O'Reilly RJ, Giralt SA, Perales MA.

Biol Blood Marrow Transplant. 2017 Jan;23(1):67-74. doi: 10.1016/j.bbmt.2016.10.017. Epub 2016 Oct 24.

25.

Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections.

Hasan AN, Selvakumar A, Shabrova E, Liu XR, Afridi F, Heller G, Riviere I, Sadelain M, Dupont B, O'Reilly RJ.

Clin Exp Immunol. 2016 Nov;186(2):249-265. doi: 10.1111/cei.12816. Epub 2016 Aug 31.

26.

Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.

Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, Castro-Malaspina H, Papadopoulos EB, Young JW, Scaradavou A, Kobos R, Giralt SA, O'Reilly RJ, Boulad F.

Biol Blood Marrow Transplant. 2016 Aug;22(8):1449-1454. doi: 10.1016/j.bbmt.2016.05.001. Epub 2016 May 13.

27.

Virus-specific T-cell banks for 'off the shelf' adoptive therapy of refractory infections.

O'Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E.

Bone Marrow Transplant. 2016 Sep;51(9):1163-72. doi: 10.1038/bmt.2016.17. Epub 2016 Apr 4. Review.

28.

Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.

Anur P, Friedman DN, Sklar C, Oeffinger K, Castiel M, Kearney J, Singh B, Prockop SE, Kernan NA, Scaradavou A, Kobos R, Curran K, Ruggiero J, Zakak N, O'Reilly RJ, Boulad F.

Bone Marrow Transplant. 2016 Jul;51(7):938-44. doi: 10.1038/bmt.2016.32. Epub 2016 Mar 21.

29.

Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS.

Dahi PB, Morawa E, Perales MA, Zabor EC, Devlin SM, Maloy M, Castro-Malaspina H, O'Reilly RJ, Papadopoulos EB, Jakubowski AA, Giralt SA.

Bone Marrow Transplant. 2016 Jul;51(7):991-3. doi: 10.1038/bmt.2016.23. Epub 2016 Feb 29. No abstract available.

30.

Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF-κB-Controlled Oxidative Stress Responses.

Shono Y, Tuckett AZ, Liou HC, Doubrovina E, Derenzini E, Ouk S, Tsai JJ, Smith OM, Levy ER, Kreines FM, Ziegler CG, Scallion MI, Doubrovin M, Heller G, Younes A, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Res. 2016 Jan 15;76(2):377-89. doi: 10.1158/0008-5472.CAN-14-2814. Epub 2016 Jan 7.

31.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.

32.

High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.

Ponce DM, Hilden P, Devlin SM, Maloy M, Lubin M, Castro-Malaspina H, Dahi P, Hsu K, Jakubowski AA, Kernan NA, Koehne G, O'Reilly RJ, Papadopoulos EB, Perales MA, Sauter C, Scaradavou A, Tamari R, van den Brink MR, Young JW, Giralt S, Barker JN.

Biol Blood Marrow Transplant. 2015 Nov;21(11):1985-93. doi: 10.1016/j.bbmt.2015.07.029. Epub 2015 Jul 31.

33.

CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.

Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2106-2114. doi: 10.1016/j.bbmt.2015.07.010. Epub 2015 Jul 14.

34.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, Xu K, Manova K, Pankov D, O'Reilly RJ, Kleppe M, McKenney AS, Shih AH, Shank K, Ahn J, Papalexi E, Spitzer B, Socci N, Viale A, Mandon E, Ebel N, Andraos R, Rubert J, Dammassa E, Romanet V, Dölemeyer A, Zender M, Heinlein M, Rampal R, Weinberg RS, Hoffman R, Sellers WR, Hofmann F, Murakami M, Baffert F, Gaul C, Radimerski T, Levine RL.

Cancer Cell. 2015 Jul 13;28(1):15-28. doi: 10.1016/j.ccell.2015.06.006.

35.

T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.

O'Reilly RJ, Koehne G, Hasan AN, Doubrovina E, Prockop S.

Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S43-50. doi: 10.1038/bmt.2015.95. Review.

36.

Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Koehne G, Hasan A, Doubrovina E, Prockop S, Tyler E, Wasilewski G, O'Reilly RJ.

Biol Blood Marrow Transplant. 2015 Sep;21(9):1663-78. doi: 10.1016/j.bbmt.2015.05.015. Epub 2015 May 29.

37.

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.

Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O'Reilly RJ, Cheung NK.

Leukemia. 2015 Nov;29(11):2238-47. doi: 10.1038/leu.2015.125. Epub 2015 May 19.

38.

Late complications of mixed chimerism following allogeneic bone marrow transplantation for thalassemia major.

Spitzer B, Giardina PJ, O'Reilly RJ, Boulad F.

Pediatr Blood Cancer. 2015 Jul;62(7):1303-4. doi: 10.1002/pbc.25498. Epub 2015 Mar 21. No abstract available.

PMID:
25810133
39.

Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts.

Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P.

Bone Marrow Transplant. 2015 Apr;50(4):493-8. doi: 10.1038/bmt.2014.302. Epub 2015 Jan 26.

40.

Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion.

Gupta MP, Coombs P, Prockop SE, Hasan AA, Doubrovina E, O'Reilly RJ, Cohen SH, Park SS, Kiss S.

Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):80-2. doi: 10.3928/23258160-20150101-14.

41.
42.

High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.

Ponce DM, Hilden P, Mumaw C, Devlin SM, Lubin M, Giralt S, Goldberg JD, Hanash A, Hsu K, Jenq R, Perales MA, Sauter C, van den Brink MR, Young JW, Brentjens R, Kernan NA, Prockop SE, O'Reilly RJ, Scaradavou A, Paczesny S, Barker JN.

Blood. 2015 Jan 1;125(1):199-205. doi: 10.1182/blood-2014-06-584789. Epub 2014 Nov 6.

43.

Human herpesvirus 6B immediate-early I protein contains functional HLA-A*02, HLA-A*03, and HLA-B*07 class I restricted CD8(+) T-cell epitopes.

Iampietro M, Morissette G, Gravel A, Dubuc I, Rousseau M, Hasan A, O'Reilly RJ, Flamand L.

Eur J Immunol. 2014 Dec;44(12):3573-84. doi: 10.1002/eji.201444931. Epub 2014 Oct 29.

44.

Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.

Dahi PB, Perales MA, Devlin SM, Olson A, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Papanicolaou G, Barker JN.

Leuk Lymphoma. 2015 Jun;56(6):1799-805. doi: 10.3109/10428194.2014.963079. Epub 2014 Oct 21.

45.

Transplantation outcomes for severe combined immunodeficiency, 2000-2009.

Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson IC, Filipovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Fuleihan RL, Haddad E, Loechelt B, Aquino VM, Gillio A, Davis J, Knutsen A, Smith AR, Moore TB, Schroeder ML, Goldman FD, Connelly JA, Porteus MH, Xiang Q, Shearer WT, Fleisher TA, Kohn DB, Puck JM, Notarangelo LD, Cowan MJ, O'Reilly RJ.

N Engl J Med. 2014 Jul 31;371(5):434-46. doi: 10.1056/NEJMoa1401177.

46.

Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.

Tyler EM, Jungbluth AA, Gnjatic S, O'Reilly RJ, Koehne G.

Cancer Immunol Res. 2014 Jun;2(6):547-58. doi: 10.1158/2326-6066.CIR-13-0174. Epub 2014 Mar 3.

47.

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.

48.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.

Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.

Blood. 2014 May 22;123(21):3296-304. doi: 10.1182/blood-2014-01-549022. Epub 2014 Apr 10.

49.

A small-molecule c-Rel inhibitor reduces alloactivation of T cells without compromising antitumor activity.

Shono Y, Tuckett AZ, Ouk S, Liou HC, Altan-Bonnet G, Tsai JJ, Oyler JE, Smith OM, West ML, Singer NV, Doubrovina E, Pankov D, Undhad CV, Murphy GF, Lezcano C, Liu C, O'Reilly RJ, van den Brink MR, Zakrzewski JL.

Cancer Discov. 2014 May;4(5):578-91. doi: 10.1158/2159-8290.CD-13-0585. Epub 2014 Feb 18.

50.

Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin.

Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, Giralt SA, Perales MA, Papadopoulos EB, Ponce DM, Young JW, Kernan NA, Scaradavou A, O'Reilly RJ, Small TN, Papanicolaou G, Barker JN.

Biol Blood Marrow Transplant. 2014 Jun;20(6):787-93. doi: 10.1016/j.bbmt.2014.02.010. Epub 2014 Feb 16.

Supplemental Content

Loading ...
Support Center